Here, we also analyzed some pharmacological inhibitors targeting NLRP3 inflammasome or AIM2 inflammasome discovered in recent years and described their mechanisms of action and therapeutic potential for experimental AAAs. Here, NLRP3 is linked to achalasia-alacrima syndrome.